Evrópusambandið - íslenska - EMA (European Medicines Agency)

rhythm pharmaceuticals netherlands b.v. - setmelanotide - offita - Ónæmiskerfi, þó ekki mataræði - imcivree is indicated for the treatment of obesity and the control of hunger associated with genetically confirmed bardet biedl syndrome (bbs), loss-of-function biallelic pro-opiomelanocortin (pomc), including pcsk1, deficiency or biallelic leptin receptor (lepr) deficiency in adults and children 6 years of age and above.

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

abcur ab* - metolazonum inn - tafla - 5 mg

Evrópusambandið - íslenska - EMA (European Medicines Agency)

ferring pharmaceuticals a/s - degarelix - blöðruhálskirtli - innkirtla meðferð - firmagon is a gonadotrophin releasing hormone (gnrh) antagonist indicated:- for treatment of adult male patients with advanced hormone-dependent prostate cancer. - for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. - as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

eisai gmbh - lenvatinib mesilat - krabbamein, nýrnafrumur - Æxlishemjandi lyf - kisplyx is indicated for the treatment of adults with advanced renal cell carcinoma (rcc):in combination with pembrolizumab, as first-line treatment (see section 5. in combination with everolimus, following one prior vascular endothelial growth factor (vegf)-targeted therapy.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

biomarin international limited - vosoritide - achondroplasia - lyf til að meðhöndla beinsjúkdóma - voxzogo is indicated for the treatment of achondroplasia in patients 4 months of age and older whose epiphyses are not closed. the diagnosis of achondroplasia should be confirmed by appropriate genetic testing.

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

alvogen ehf. - goserelinum acetat - vefjalyf í áfylltri sprautu - 3,6 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

baxter medical ab* - mesnum inn - stungulyf, lausn - 100 mg/ml

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

astrazeneca ab - goserelinum acetat - vefjalyf - 10,8 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

astrazeneca ab - goserelinum acetat - vefjalyf - 3,6 mg

Evrópusambandið - íslenska - EMA (European Medicines Agency)

accord healthcare s.l.u. - degarelix acetate - blöðruhálskirtli - other hormone antagonists and related agents - degarelix accord is a gonadotrophin releasing hormone (gnrh) antagonist indicated:for treatment of adult male patients with advanced hormone-dependent prostate cancer. for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.